Vaxart terminates at-the-market equity offering agreement with Cantor, B. Riley

Vaxart, Inc.

Termination effective October 18, 2024; no termination penalties incurred.
From Sept 2021 to Oct 2024, Vaxart sold 17.5M shares for ~$28.6M gross proceeds under the ATM.
After termination, Vaxart may not offer or sell additional shares under the Sales Agreement.
No reason for termination disclosed; may signal a shift in capital-raising strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.